Efficacy of recombinant human club (clara) cell 10kDa protein (CC10) administered to premature neonates with respiratory distress syndrome.

Registry ID

EUCTR2015-000253-21

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Therabron Therapeutics Inc.

Start date

2015-09-15

Completion date

2018-05-29

Last update

2026-08-16

Conditions

• Bronchopulmonary Dysplasia (BPD)

Summary

To determine the efficacy of a single intratracheal dose of rhCC10 (1.5mg/kg and 5mg/kg in a 2 ml/kg fixed volume) in improving survival without chronic respiratory morbidity as indicated by a reduction in respiratory complications at 12 months corrected gestational age.

Locations

• , , France
• , , Poland

Related clinical trials

• Chloride Imbalance in Preterm Infants
• Continued Pressure for Alveolar Protection (CPAP Trial)
• PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia
• Enteral Lipid Supplementation and Bronchoplumonary Dysplasia of Premature Infants
• Characterization of Extracellular Vesicles From the Cord Blood of Extremely Preterm New Borns and Their Correlation With Severe Morbidity and Mortality
• Metformin for Premature Infants With Bronchopulmonary Dysplasia

View on source registry